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Methods and Analysis:
In accordance with the PRISMA guidelines, a systematic review of all medical research literature that investigates defensive medicine will be performed by two independent reviewers. The databases PubMed, Embase and Cochrane will be systematically searched on the basis of predetermined criteria. Data from all included European studies will systematically be extracted including the studies' definitions and understandings of defensive medicine, especially the types of motives for medical actions that each study regards as defensive.
Ethics and Dissemination:
No ethics clearance is required as no primary data will be collected. The results of the systematic review will be published in a peer-review journal.
Strengths and limitations of this study
 The systematic review will be based on a systematic and thorough search of literature independently performed by two reviewers following the PRISMA guidelines hereby increasing the generalisability and reliability of the findings. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The term originates from the US (3) and has since then taken on various connotations (4) . The most commonly used definition describes DM as physicians' deviations from sound medical practice due to fear of liability claims and lawsuits (5) (6) (7) (8) (9) . DM can additionally be subdivided into two main forms of behaviour: 1. positive DM (also named either active DM or assurance behaviour), which involves physicians ordering extra diagnostic tests, procedures or visits and 2. negative DM (also named passive DM or avoidance behaviour) which is the avoidance of high-risk patients or procedures. Both forms aim to reduce physicians' exposure to malpractice liability (5) (6) (7) (8) . The above definition of DM consists of two components: A medical action and an underlying motive for acting defensively.
DM has been associated with rising health care costs (8) . Furthermore, it has been associated with overtreatment, -prescription and -diagnosing of patients and decreased trust in the physician-patient relationship, leading physicians to regard patients as potential plaintiffs (8, (10) (11) (12) (13) . Moreover, physicians report patient disrespect for their professionalism, personal frustration among physicians, and inequality in healthcare as possible consequences of defensive medicine (14, 15) .
In the US, DM is reported to be frequent (16) . The number of lawsuits for medical malpractice has risen significantly in the US (10), and DM has been shown to be directly related to this growth (13) .
US physicians are forced to hold expensive malpractice insurances in order to cover the cost from malpractice suits (17) . Hence, with inadequate legislation protecting physicians from tort, concerns about malpractice liability is likely to be the predominant reason to act defensively (8) . Indeed, negative associations have been found between physicians' use of medical resources and risk of malpractice claims (18) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 In several European countries malpractice litigation is reported to happen less frequently than in the US, e.g. in The Netherlands (3, 19) Denmark (14) , Switzerland (20) , and the UK (21) . Furthermore, in some European countries, the medico-legal system protects the physicians who are not held financially liable for malpractice or other treatment related adverse events. In addition, the patients are instead compensated by the government (known as a no-fault system) (22) (23) (24) .
Nevertheless, DM seems also to be prevalent in Europe, e.g. Denmark (14) , the UK (25), Italy (13), Belgium (26), The Netherlands (3), Germany (27) and Switzerland (21) , and a substantial part of research on DM seems to originate from Europe.
Variations in medico-legal systems between the US and most European countries raise the question
whether the definition of DM, as actions motivated primarily by litigious concerns, holds true in European countries where physicians are not subjected to tort legislation (21) and if other motives for performing defensive medical actions are documented in the European literature on DM (28) .
Rationale
To our knowledge no systematic review exists of how DM is defined and understood in the European medical literature. A systematic review of the term "defensive medicine" in the European context will provide a more nuanced understanding of this complex and non-beneficial phenomenon, hereby increasing the possibilities to reduce the practice of DM in future health care.
Objectives
The aim of this study is to present a protocol paper for a systematic review with the following objective: To analyse variations in the definition and understandings of the term "defensive medicine" in European research articles. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
METHODS

Patient and Public Involvement
Patients or the public were not involved in the design, or conduct, or reporting, or dissemination of our research.
Protocol
This protocol for a systematic review is conducted in accordance with the PRISMA-P (Preferred Reporting Items for Systematic Reviews -Protocol) (29) .
Eligibility criteria
Publications will be included in the review based on the following criteria:
Inclusion criteria:
1. The terms "defensive medicine" or "defensive practice" are stated in title or abstract.
2. The study is available in full-text and written in English language.
3. DM is performed by physicians.
4.
The study is an original research study or systematic review published in a medical journal. 5. DM is stated as part of the study's aim/objective in at least one of the following ways: a. DM is included in the publication's aim/objective. b. DM is implicitly a significant part of the aim/objective. Further 6. The study's research data includes data from Europe.
Information sources
Eligible studies will be searched in three databases: PubMed, Embase and Cochrane. 
Search strategy
The preparation of search strategy is based on the term "defensive medicine". In accordance with the database PubMed, the MeSH term "defensive medicine" is combined with the entry terms "defensive practice", "defensive practices" and "medicine, defensive". On the basis of this, the following search strategy will be used: "defensive medicine OR defensive practice OR defensive practices OR medicine, defensive", see appendix. All references in the papers fulfilling the inclusion criteria will be examined in order to identify potentially neglected studies. The literature search will be updated before the final analysis. See appendix for detailed search strategy.
Study records
Data management
Publications found by the search strategy will be exported into the reference management software (EndNote) (30) and the software Covidence (31) , where the systematic screening and data extraction will be performed, including the removing of duplicates. Number of citations for each study will be assessed with Web of Science (32) in accordance with the PRISMA guidelines (29) .
Selection process
Two independent reviewers (NBP and PSJJ) will screen all potentially relevant studies in a two-phase screening process to ensure compliance with the inclusion criteria and eligibility by use of Covidence (31) . NBA and PSJJ will discuss and resolve any disagreements to reach consensus. If consensus is not achievable, a third reviewer (JL) will be involved in the discussion and finally decide whether the study in question is to be included or not. 
Data collection process
The primary authors (NBP and PSJJ) will extract data from the included studies, including publication details (author(s), name of journal, year of publication), study characteristics (design, country of origin, sample size, medical speciality investigated, and number of citations), study objective, stated definition of DM and understandings of DM.
Quality assessment
The two reviewers (NBP and PSJJ) will independently assess the quality of each study. The qualitative studies will be reviewed using the Critical Appraisal Skills Programme (CASP) (33), recommended by the Centre for Clinical Guidelines (CFKR) (34), to ensure a critical and standardized assessment of the quality and analysis of the study. The quantitative studies will be reviewed using a cross-sectional appraisal tool with questions adapted from Guyatt GH et al. JAMA 1993 and 1994 (35, 36) . The systematic reviews and meta-analysis will be reviewed using Assessing the Methodological Quality of Systematic Reviews (AMSTAR) (37) recommended by the Centre for Clinical Guidelines (CFKR) (34). Disagreements will be discussed until consensus is reached.
Data items
Data items are as stated above under "methods". The design of the review is based on the hypothesis that a definition of DM reflects the medico-legal context in which it is used. Therefore, we expect the definitions stated and understandings of DM in the European research literature to be different than those stated in the literature deriving from the US. For each paper, the stated definition and understanding of DM will be extracted by the first author (NBP). The definition of DM will be identified as: "DM is…", "DM is defined as…", "DM refers to…", or "DM is characterized by…". If no definition of DM is stated, the way in which DM is introduced will be identified. A paper's understanding of DM is assessed from its use in the study and may differ from the stated definition. Quotes identifying how DM is understood will be extracted and analysed according to a thematic analysis approach aiming to categorize the findings. Based on the above definitions of DM, it is expected that the vast majority of papers will define DM as healthcare actions conducted by healthcare professionals during their work, but that the motives making the actions defensive may differ between papers showing a broader understanding of DM in some European studies than according to the US definition. Thus, for each paper, the motives regarded as defensive will be identified in the texts, tables, figures, as well as in the data collection methods. The identified categories of DM definitions and understandings will be scrutinized by the author group.
Data synthesis
Outcomes and prioritization
The review's main outcomes will be a categorisation of the identified definitions of DM in the European medical research literature focusing on the motives for medical acting that the studies regard as defensive and a graphical display of the historical trend in the annual number of published European original research papers regarding DM divided on the identified categories of DM definitions.
Risk of bias in individual studies
Since the objective of this study differs from most reviews by not taking interest in the results found by the reviewed studies, the quality assessment of the identified papers serves a different purpose. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The quality of the papers is used to show whether high quality papers use a different definition of DM than other papers. See the above described quality assessment procedure.
Conclusion
This systematic review will address the variations in the definition and understandings of the term "defensive medicine" in European research articles. This review will provide a more nuanced understanding of this complex and non-beneficial phenomenon, hereby increasing the possibilities to reduce the practice of DM in future health care.
Potential amendments
We do not envisage any amendments to the present protocol. However, should an amendment be necessary, it will be notified, registered and reported.
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PRISMA-P 2015 Checklist
This checklist has been adapted for use with protocol submissions to Systematic Reviews from Table 3 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45 Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review
Information sources 9 Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage
Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated
STUDY RECORDS
Data management 11a Describe the mechanism(s) that will be used to manage records and data throughout the review
Selection process 11b State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)
Data collection process 11c
Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators
Data items 12
List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications
Outcomes and prioritization 13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale
Risk of bias in individual studies 14
Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis x 10-11
DATA
15a Describe criteria under which study data will be quantitatively synthesized
If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I 2 , Kendall's tau)
x 15c
Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, metaregression)
x
Synthesis
15d If quantitative synthesis is not appropriate, describe the type of summary planned x 9-10
Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)
Confidence in cumulative evidence 17
Describe how the strength of the body of evidence will be assessed (e.g., GRADE) x 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45 The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence -details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.
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Methods and Analysis:
In concordance with the PRISMA guidelines, a systematic review of all medical research literature that investigate defensive medicine will be performed by two independent reviewers. The databases PubMed, Embase and Cochrane will be systematically searched on the basis of predetermined criteria. Data from all included European studies will systematically be extracted including the studies' definitions and understandings of defensive medicine, especially the motives for doing medical actions that the study regards as "defensive".
Ethics and Dissemination:
No ethics clearance is required as no primary data will be collected. The results of the systematic review will be published in a peer-reviewed, international journal.
Strengths and limitations of this study
Strengths:
 The present systematic review will be based on a systematic and thorough search of literature independently performed by two reviewers concordant with the PRISMA guidelines, hereby increasing the generalisability and reliability of the findings.
 The scientific quality of each reviewed study will be assessed by use of standardised quality assessment tools and only the content of peer-reviewed original research papers will be included in the analysis. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Limitations:
 Only English language studies will be included in the systematic review. DM has been associated with rising health care costs (7) . Furthermore, it has been associated with overtreatment, -prescription and -diagnosing of patients and decreased trust in the physician-patient relationship, leading patients to mistrust physicians' motivations and physicians to regard patients as potential plaintiffs (7, (9) (10) (11) (12) . Moreover, physicians report patient disrespect for their professionalism, personal frustration, and inequality in healthcare as possible consequences of defensive medicine (13, 14) .
In the US, DM is reported to be frequent (15) . The number of lawsuits for medical malpractice has risen significantly (9) , and DM has been shown to be directly related to this growth (12) . US physicians are forced to hold expensive malpractice insurances in order to cover the cost from 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (16) . Hence, with inadequate legislation protecting physicians from tort, concerns about malpractice liability is likely to be the predominant reason to act defensively (7) . Indeed, negative associations have been found between physicians' use of medical resources and risk of malpractice claims (17) .
In several European countries malpractice litigation is reported to happen less frequently than in the US, e.g. in the Netherlands (2, 18) Denmark (13) , Switzerland (19) , and the UK (20) . In these countries, the medico-legal system does not hold physicians financially liable for malpractice or other treatment related adverse events. The patients are instead compensated by the government (known as a no-fault system) (21) (22) (23) . Nevertheless, DM seems also to be prevalent in Europe, e.g. Denmark (13) , the UK (24), Italy (12) , Belgium (25), The Netherlands (2), Germany (26) and Switzerland (20) .
Furthermore, a substantial part of research on DM seems to originate from Europe. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The aim of this study is to present a protocol paper for a systematic review with the following objective: To analyse variations in the definitions and understandings of the term "defensive medicine" in European research articles.
Variations in medico-legal systems between the US and most
METHODS
Patient and Public Involvement
Protocol
This protocol for a systematic review is conducted in concordance with the PRISMA-P (Preferred Reporting Items for Systematic Reviews -Protocol) (28) .
Eligibility criteria
Inclusion criteria: 1. One or both of the terms "defensive medicine" and "defensive practice" are stated in title or abstract.
3. DM is performed by physicians, including general practitioners, as well as physicians from medical, surgical and paraclinical specialities.
4.
The study is an original research study (quantitative or qualitative primary research) or systematic review published in a peer-reviewed, medical journal. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Information sources
Eligible studies will be searched in three databases: PubMed, Embase and Cochrane, 3 rd of February 2020.
Search strategy
The preparation of search strategy is based on the original American term "defensive medicine". In accordance with the database PubMed, the MeSH term "defensive medicine" is combined with the entry terms "defensive practice", "defensive practices" and "medicine, defensive". On the basis of this, the following search strategy will be used: "defensive medicine OR defensive practice OR defensive practices OR medicine, defensive". All references in the papers fulfilling the inclusion criteria will be examined in order to identify potentially neglected studies. The literature search will be updated before the final analysis. See appendix for detailed search strategy.
Study records
Data management
Publications found by the search strategy will be exported into the reference management software (EndNote) (29) and the software Covidence (30) , where the systematic screening and data extraction 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 will be performed, including the removing of duplicates. Number of citations for each study will be assessed with Web of Science (31) in concordance with the PRISMA guidelines (28) .
Selection process
Two independent reviewers (NBP and PSJJ) will screen all potentially relevant studies in a two-phase screening process to ensure interrater reliability, compliance with the inclusion criteria and eligibility by use of Covidence (30) . NBA and PSJJ will discuss and resolve any disagreements to reach consensus. If consensus is not achievable, a third reviewer (JL) will be involved in the discussion and finally decide whether the study in question is to be included or not.
Data collection process
The primary authors (NBP and PSJJ) will extract data from the included studies, including publication details (author(s), name of journal, year of publication), study characteristics (design, country of origin, sample size, medical speciality investigated, and number of citations), study objective, stated definitions of DM and understandings of DM.
Quality assessment
The two reviewers (NBP and PSJJ) will independently assess the quality of each study. The qualitative studies will be reviewed using the Critical Appraisal Skills Programme (CASP) (32), recommended by the Centre for Clinical Guidelines (CFKR) (33) , to ensure a critical and standardized assessment of the quality and analysis of the study. The quantitative studies will be reviewed using a cross-sectional appraisal tool with questions adapted from Guyatt GH et al. JAMA 1993 and 1994 (34, 35) . The systematic reviews will be reviewed using Assessing the Methodological 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Quality of Systematic Reviews (AMSTAR) (36) recommended by the Centre for Clinical Guidelines (CFKR) (33) . Disagreements will be discussed until consensus is reached.
Data items
Data items are as stated above under "methods". The design of the review is based on the hypothesis that a definition of DM reflects the medico-legal system in which it is used. Therefore, we expect the definitions and understandings of DM stated in the European research literature to be different than those stated in the literature deriving from the US.
Data synthesis
For each paper, the stated definition and understanding of DM will be extracted by the first author (NBP). The definition of DM will be identified as: "DM is…", "DM is defined as…", "DM refers to…", or "DM is characterized by…". If no definition of DM is stated, the way in which DM is introduced will be identified. A paper's understanding of DM is assessed from its use in the study and may differ from the stated definition. Quotes identifying how DM is understood will be extracted and analysed according to a thematic analysis approach aiming to categorize the different understandings. Based on the above definitions of DM, it is expected that the vast majority of papers will define DM as healthcare actions conducted by healthcare professionals during their work, but that the motives making the actions defensive may differ between papers showing a broader understanding of DM in some European studies than according to the US definition. Thus, for each paper, the motives regarded as defensive will be identified in the texts, tables, figures, as well as in the data collection methods. The identified categories of DM definitions and understandings will be scrutinized by the author group. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Risk of bias in individual studies
Since the objective of this study differs from most systematic reviews by not taking interest in the results found by the reviewed studies, the quality assessment of the identified papers serves a different purpose. The assessment of the quality of the papers is used to show whether high quality papers use a different definition of DM than other papers (see the above described quality assessment procedure).
Although there are multiple languages used in Europe, the review only includes English scientific literature. However, most high-ranking scientific journals reporting on DM is written in English and we specifically aim to support future research on DM. Furthermore, DM was originally conceptualized in English.
Conclusion
This systematic review will address the variations in the definitions and understandings of the term "defensive medicine" in European research articles. This review seeks to provide a more nuanced understanding of the complex and non-beneficial phenomenon of defensive medicine, hereby supporting the quality of future research on the topic. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Potential amendments
We do not envisage any amendments to the present protocol. However, should an amendment be necessary, it will be notified, registered and reported. The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Open Access shall be governed by a Creative Commons licence -details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.
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